Novartis to Acquire Synnovation Therapeutics’ Pan-Mutant Selective PI3Kα Inhibitor Program
Synnovation will receive total cash consideration of up to $3 billion, consisting of $2 billion in upfront cash…
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Novartis Pharma AG Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor…
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Novartis Pharma AG Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor…